Literature DB >> 9443474

Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype.

S Craft1, E Peskind, M W Schwartz, G D Schellenberg, M Raskind, D Porte.   

Abstract

Patients with Alzheimer's disease (AD) have elevations of fasting plasma insulin that are hypothesized to be associated with disrupted brain insulin metabolism. We examined paired fasted plasma and CSF insulin levels in 25 patients with AD and 14 healthy age-matched adults and determined whether insulin levels were related to severity of dementia and apolipoprotein E-epsilon4 homozygosity, a known genetic risk factor for AD. The AD patients had lower CSF insulin, higher plasma insulin, and a reduced CSF-to-plasma insulin ratio when compared with healthy adults. The differences were greater for patients with more advanced AD. Patients who were not apolipoprotein E-epsilon4 homozygotes had higher plasma insulin levels and reduced CSF-to-plasma ratios, whereas epsilon4 homozygotes with AD had normal values. Both plasma and CSF insulin levels are abnormal in AD, and there are metabolic differences among apolipoprotein E genotypes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443474     DOI: 10.1212/wnl.50.1.164

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  172 in total

1.  Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

Authors:  L Gasparini; G K Gouras; R Wang; R S Gross; M F Beal; P Greengard; H Xu
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Polyadenylation of nascent RNA during the embryogenesis of Ilyanassa obsoleta.

Authors:  J R Collier
Journal:  Exp Cell Res       Date:  1975-10-15       Impact factor: 3.905

Review 3.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  Type 2 diabetes and risk of cognitive impairment and dementia.

Authors:  Rachel A Whitmer
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

5.  Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults.

Authors:  Amber S Watts; Natalia Loskutova; Jeffrey M Burns; David K Johnson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  Cognitive decline and cardiometabolic risk among Hispanic and non-Hispanic white adults in the San Luis Valley Health and Aging Study.

Authors:  Kerry L Hildreth; Jim Grigsby; Lucinda L Bryant; Pamela Wolfe; Judith Baxter
Journal:  J Behav Med       Date:  2013-01-18

7.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

Review 8.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

Review 9.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

10.  Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI.

Authors:  T den Heijer; S E Vermeer; E J van Dijk; N D Prins; P J Koudstaal; A Hofman; M M B Breteler
Journal:  Diabetologia       Date:  2003-11-01       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.